Magistral drugs in hospitalized newborns and children

Agueda Cabral de Souza Pereira, Elaine Silva Miranda, Selma Rodrigues de Castilho, Débora Omena Futuro, Lenise Arneiro Teixeira, Geraldo Renato de Paula*

Universidade Federal Fluminense (UFF), Niterói, RJ, Brazil

Received 4 November 2015; accepted 22 February 2016
Available online 26 July 2016

Abstract

Objective: Study the use of magistral oral solutions and suspensions in infants and children at a university hospital.

Methods: This is a descriptive study based on the analysis of the assessed hospital's magistral drug request forms regarding the patients in the neonatal ICU, Obstetrics, Pediatrics and Pediatric Emergency from January 2012 to December 2013. The frequency of drug requests and dispensation was evaluated and the consumption of each active ingredient of the preparations was expressed as number of “infant defined daily dose” (iDDD) and of iDDD/100 bed-days.

Results: A total of 657 forms were analyzed—a monthly average of 27 pediatric preparations. The neonatal ICU accounted for 69.6% of these requests. Twenty-one drug items were used, of which the most common were folinic acid (88 requests), sulfadiazine (85) and captopril (73). The consumption of the active principle in these preparations varied in number of iDDD, from 7.5 (hydralazine) to 16,520.0 (folic acid), and in number of iDDD/100 bed-days in the neonatal ICU, from 0.1 (zinc sulfate) to 146.1 (folic acid).

Conclusions: The constant consumption of magistral oral solutions and suspensions by newborns and children of the assessed hospital indicates the need for such preparations as a pediatric therapeutic alternative in this hospital.

© 2016 Sociedade de Pediatria de São Paulo. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

* Corresponding author.
E-mail: geraldopaula@vm.uff.br (G.R. Paula).

http://dx.doi.org/10.1016/j.rppede.2016.02.012
2359-3482/© 2016 Sociedade de Pediatria de São Paulo. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Medicamentos magistrais em recém-nascidos e crianças hospitalizados

Resumo
Objetivo: Estudar o uso de soluções e suspensões orais magistrais em recém-nascidos e crianças de um hospital universitário.
Métodos: Foi feito um estudo descritivo a partir da análise dos formulários de solicitação de manipulação do hospital estudado referentes aos pacientes da UTI-neonatal, obstetrícia, pediatria e emergência pediátrica de janeiro de 2012 a dezembro de 2013. As frequências das solutações e dispensações desses medicamentos foram avaliadas e o consumo de cada princípio ativo das preparações foram expressos sob a forma de número de infant defined daily dose (iDDD) e de iDDD/100 leitos-dia.
Resultados: Foram analisados 657 formulários–média mensal de 27 preparações pediátricas. A UTI-neonatal foi responsável por 69,6% dessas solicitações. Foram usados 21 itens de medicamentos, destacou-se o uso de ácido fólico (88 solicitações), sulfadiazina (85) e captopril (73). O consumo de princípio-ativo nessas preparações variou, em número de iDDD, de 7,5 (hidralazina) a 16.520 (ácido fólico) e em número de iDDD/100 leitos-dia da UTI-neonatal, de 0,1 (sulfato de zinco) a 146,1 (ácido fólico).
Conclusões: O consumo constante das soluções e suspensões orais magistrais pelos recém-nascidos e crianças do hospital estudado indica a necessidade dessas preparações como opção terapêutica pediátrica nesse hospital.
© 2016 Sociedade de Pediatria de São Paulo. Publicado por Elsevier Editora Ltda. Este é um artigo Open Access sob uma licença CC BY (http://creativecommons.org/licenses/by/4.0/).

Introduction

Newborns and children go through physiological changes throughout their development, which interfere with the pharmacokinetics and, consequently, the safety and effectiveness of drug treatment in the pediatric age group. Therefore, studies are needed in each pediatric subpopulation for which their use is intended aiming at safety and efficacy assessment of pediatric drugs.¹

However, there is a shortage of pediatric drugs in the pharmaceutical industry, which can be explained by economic, ethical and technical issues. This fact makes the magistral preparations advantageous options for obtaining medications with appropriate pharmaceutical form for pediatric use, as they allow dose flexibility and easy drug administration.¹,²

In Brazil, the preparation of compounded drugs must comply with the rules of the Collegiate Board Resolution (RDC) 67/2007, which provides for Good Compounding Practices of Magistral and Compounded Drugs for Human Use in pharmacies.³ To obtain magistral solutions and oral suspensions, the first choice is the compounding of the active principle; however, these can also be obtained by diluting a liquid formulation (e.g., an injectable dilution), provided it is compatible with oral administration, by pulverizing tablets or removing the powder from the capsule.⁴

This study aims to evaluate the use of magistral oral solutions and suspensions in hospitalized newborns and children.

Method

A descriptive, retrospective study was carried out based on the analysis of request forms for compounding of oral liquid preparations for newborns and children admitted at Hospital Universitário Antônio Pedro (HUAP) of Universidade Federal Fluminense (UFF), related to the period of January 2012 to December 2013. This is a tertiary and quaternary hospital, has 287 beds and serves the population of the Metropolitan Region II of the State of Rio de Janeiro.

The pediatric oral liquid preparations mentioned in this study were prepared at the pharmacy of the UFF, under the responsibility and guidance of a pharmacist, with formulations being based on scientific literature, with adequate validity and packaging, as well as correct storage recommendations, quality control procedures and medication traceability.

The frequencies of requests for pediatric compounded oral liquid formulations in relation to: the month of request; their active principle; their Anatomical-Therapeutic-Chemical (ATC) classification,⁵ and requesting sectors were calculated.

The administration frequency of magistral oral solutions and suspensions was analyzed for total oral use liquid pharmaceutical forms dispensed by the hospital pharmacy to the neonatal intensive care unit and Pediatrics in 2013.

The annual consumption of infant defined number of daily dose (iDDD), which corresponds to 1/10 of the defined daily dose (DDD), was calculated for each active principle of these preparations, assuming the complete consumption of the compounded product. The number of iDDD/100 bed-days was also calculated for patients in the NICU.⁶ The total occupation of beds in this sector was considered to calculate the number of beds in the NICU.

Descriptive statistics tools such as mean, standard deviation and frequency distributions were used for data analysis. This study was approved by the Institutional Review Board of the UFF (n. 765.880 de 08/08/2014).
Table 1  Use of non-licensed manipulated oral liquid preparations for newborns and children at a hospital in 2012 and 2013 (n=657).

| Magistral oral solution/suspension | Frequency of requests for newborns and children in 2012 and 2013 | Established oral IDDD (mg) | N. of IDDD consumed by newborns and children in 2012 | N. of IDDD consumed by newborns and children in 2013 | N. of IDDD/100 bed-days consumed by the NICU in 2012 and 2013 |
|-----------------------------------|---------------------------------------------------------------|---------------------------|------------------------------------------------------|------------------------------------------------------|---------------------------------------------------------------|
| Folic acid                        | 11                                                           | 0.04                      | 12,625.0                                              | 3,900.0                                              | 146.1                                                         |
| Folinic acid                      | 88                                                           | 6                         | 178.3                                                 | 237.5                                                | 2.6                                                           |
| Ursodeoxycholic acid              | 5                                                            | 75                        | 61.3                                                  | 20.0                                                 | 0.6                                                           |
| Amiodarone                        | 1                                                            | 20                        | 48.0                                                  | 0                                                     | 0                                                             |
| Caffeine                          | 53                                                           | 40                        | 212.5                                                 | 226.3                                                | 4.0                                                           |
| Captopril                         | 73                                                           | 5                         | 2842.0                                                | 1652.0                                               | 21.8                                                          |
| Sodium citrate                    | 2                                                            | a                         | b                                                     | b                                                    | b                                                             |
| Enalapril                         | 6                                                            | 1                         | 420.0                                                 | 660.0                                                | 0.0                                                           |
| Spirinolactone                    | 67                                                           | 7.5                       | 1132.8                                                | 788.0                                                | 9.7                                                           |
| Fluconazole                       | 4                                                            | 20                        | 75.0                                                  | 130.0                                                | 0                                                             |
| Furosemide                        | 63                                                           | 4                         | 2558.8                                                | 1655.0                                               | 11.8                                                          |
| Hydralazine                       | 1                                                            | 10                        | 7.5                                                   | 0                                                     | 0                                                             |
| Hydrochlorothiazide               | 43                                                           | 2.5                       | 1976.0                                                | 1848.0                                               | 33.3                                                          |
| Pyrazinamide                      | 2                                                            | 150                       | 64.0                                                  | 0                                                     | 0                                                             |
| Pyridoxine                        | 1                                                            | 16                        | 937.5                                                 | 0                                                     | 0                                                             |
| Pyrimethamine                     | 63                                                           | 7.5                       | 528.7                                                 | 338.0                                                | 4.9                                                           |
| Propranolol                       | 4                                                            | 16                        | 10.3                                                  | 0                                                     | 0.1                                                           |
| Ranitidine                        | 18                                                           | 30                        | 232.5                                                 | 186.3                                                | 3.8                                                           |
| Sildenafil                        | 55                                                           | 5                         | 621.6                                                 | 282.0                                                | 4.9                                                           |
| Sulfadiazine                      | 85                                                           | 60                        | 2971.7                                                | 3041.7                                               | 36.5                                                          |
| Zinc sulfate                      | 12                                                           | 60                        | 12.3                                                  | 6.7                                                   | 0.1                                                           |

a  Either DDD or iDDD was not identified for sodium citrate.
b  It was not possible to calculate the number of iDDD consumed by newborns and children and the number of iDDD/100 bed-days consumed by the NICU regarding the oral solutions of sodium citrate due to lack of information on DDD or iDDD for sodium citrate.

Results

The study analyzed 657 compounding request forms for oral liquid preparations intended for infants and children in the NICU, obstetrics (rooming-in newborns), pediatrics and pediatric emergency services.

Of the assessed newborn and infant services, the NICU was the unit with the highest number of requests (457; 69.6%), followed by pediatrics (99; 15.1%), obstetrics (71, 10, 8%); pediatric emergency (27; 4.1%) and non-identified sector (3, 0.4%).

Per month, an average of 27 magistral oral solutions and suspensions (standard deviation=9.8) were requested. The months with the highest and lowest number of requests were in March 2013 (45 requests) and December 2012 and November 2013 (both with 10 requests), respectively.

The most often requested drug classes during the study period, according to the ATC, were: C-cardiovascular system (258 requests—especially captopril, spironolactone and furosemide); J-anti-infective for systemic use (91 requests—mainly sulfadiazine) and V-varied (88 requests—corresponding to folic acid). The least requested class was B—blood and blood-forming organs (13 requests—corresponding to folic acid and sodium citrate).

In 2013, 318 liquid pharmaceutical forms for oral use were dispensed to the NICU and 900 to the Pediatrics unit, of which 209 (65.7%) and 40 (4.4%) were compounded oral solutions and suspensions, respectively.

The frequencies of requests for pediatric compounded oral solutions and suspensions were calculated in relation to the active principle requested for these preparations. The consumption of active principle through the iDDD number of these medications in infants and children was also calculated, as well as the number of iDDD/100 bed-days of patients in the NICU (Table 1).

Discussion

The need for the use of magistral preparations to cope with the lack of oral liquid formulations from the pharmaceutical industry was demonstrated in this study, which identified 657 magistral oral solutions and suspensions, regarding 21 different active principles, which have been used in the treatment of newborns and children at HUAP in 2012 and 2013. It is noteworthy that the main characteristics of the assessed hospital are: being a public hospital; providing middle- and high-complexity care; providing specialized outpatient care, urgent, emergency care and hospital admission to patients from the Unified Health System; in addition to teaching (Graduation, Post-Graduation, medical and multiprofessional residency) and research activities, characteristics that are similar to other Brazilian university hospitals.

Other studies also demonstrated the need for these solutions and suspensions for pediatric therapy. Modifications of pharmaceutical drug forms have been reported by Oguz
et al. and Khdour et al., who identified, respectively, 20.5% and 5.8% modifications in requests. Costa et al. found 119 drug adaptations from solid to liquid form and Gavriliou et al. identified two dose modifications in pharmaceutical forms. Dos Santos and Heineck found that 79 prescription items involved extemporaneous preparations. Extemporaneous compounded oral preparations are magistral drugs that should be used within 48 hours. Important regulatory initiatives were developed in Europe, United States and Australia to increase the number of available pediatric drugs, but Brazil still lacks specific regulation for the registration and use of pediatric drugs and an incentive policy regarding pediatric research.

Oral solutions and suspensions compounded by the hospital pharmacy or prepared through the modification of the pharmaceutical form performed by the nursing staff are often studied in the category of unlicensed drug use. The definition of unlicensed drug use in pediatrics includes those originated from licensed drugs modifications, such as those that underwent pharmaceutical form modification, those without authorization to be sold from the regulatory agency, imported drugs, the contraindicated drugs and those that have no information on use in this population—although there are divergences among specialists.

The use of unlicensed and off-label medications (of which use is unauthorized by a regulatory agency) in pediatric patients has been the subject of several studies, as they are often prescribed to this population, particularly newborns, despite the high frequency of adverse reactions associated with their use. Magalhães et al. found that unlicensed drug use in hospitalized pediatric patients occurs in many countries, such as Brazil, Sweden, Croatia, Turkey, Estonia, Netherlands, Palestine, France, Italy, Germany, Finland, Switzerland, Serbia, Spain, Israel and England. In Brazil, there are few studies on the use of magistral drugs in infants and children, which are concentrated in hospitals from only three Brazilian cities: Fortaleza, Porto Alegre, and Belo Horizonte.

Observing the profile of oral solutions and suspensions compounded for newborns and children of the studied hospital, it was verified that solutions/suspensions of these active principles were identified in other studies: folic acid, folinic acid, ursodeoxycholic acid, captopril, enalapril, fluconazole, furosemide, hydrochlorothiazide, propranolol, ranitidine, pyrimethamine, and sulfadiazine. Therefore, it is observed that the demand for oral solutions and suspensions administered to newborns and children in this study has also been observed in other studies and that the compounding of drugs is a national and international necessity due to the lack of oral liquid drugs from the pharmaceutical industry.

However, it is important to note that some medications that require compounding to be obtained in oral liquid formulation in a certain country may be available in others. In the United States, for instance, the following drugs are approved by FDA and sold as oral solution: caffeine, enalapril, fluconazole, furosemide, propranolol, ranitidine, and sildenafil.

Regarding the recipients of the magistral oral solutions and suspensions, it was observed in the studied hospital that newborns are the main recipients of these formulations and that the NICU is responsible for 70% of these requests. This result is in accordance with that identified by Magalhães et al., which indicate that most unlicensed drugs are prescribed for newborns and often for preterm infants.

The comparison of results on medication use in this study with those of other studies was hindered by methodological differences. Other authors chose to analyze magistral drugs as cases of unlicensed medication use and expressed results as relative frequency (%) of unlicensed items in prescriptions, prescriptions that included unlicensed items and/or patients who received unlicensed drugs. The present study concentrated on oral solutions and suspensions and expressed its results, mainly regarding the amount of active principle consumed in milligrams per number of iDDD and number of iDDD/100 bed-days. The choice of showing the results of this study in relation to iDDD was based on the recommendation made by the WHO on the use of DDD in drug use studies.

It should be observed that the pharmaceutical service division, responsible for adapting active ingredients and/or drugs available on the market for administration in hospitalized patients, is scarce in Brazilian hospitals, including the studied hospital. Thus, working with the compounding pharmacy is very important to allow the obtaining of magistral drugs necessary for the treatment of newborns and children.

Costa et al. reported that the lack of the drug in appropriate presentation for patient administration led the nursing staff to make dosage form changes when treating patients. Of the pharmaceutical form adaptations, 75.63% had an inappropriate vehicle and there were also cases of incorrect packaging and conservation.

Among the study limitations are the fact that a single hospital was studied, assuming that each requested preparation was consumed in full and that the NICU occupancy rate was 100% during the studied period. However, it is noteworthy that the studied hospital profile is similar to that of other university hospitals. Additionally, the compounded medication was prepared for a specific patient and had a small volume and narrow expiration date, making it reasonable to assume that the compounded medication was consumed in full. Regarding occupation, the studied hospital is a public reference health unit, which provides care to the population of a densely populated area and the occupancy of 100% of beds is justifiable. Thus, the generalization of the results must take these aspects into account.

It is noteworthy that the use of magistral drugs may be a good therapeutic option for infants and children. However, regulatory incentives are needed for the pharmaceutical industry to produce these drugs at adequate dosage for this population.

Funding

This study did not receive funding.

Conflicts of interest

The authors declare no conflicts of interest.
References

1. Méndez Esteban ME, Antequera Rodríguez-Rabadán J, Puebla García V, Pardo de Torres J, Gallego Lago V, Herreros de Tejada A. Formulaciones orales acuosas: uma administração mais segura para pediatria. Rev O F I L. 2006;16:15–28.

2. Pinto S, Barbosa MC. Medicamentos manipulados em pediatria: estado actual e perspectivas futuras. ARQUIMED. 2008;22:75–84.

3. Brazil—Ministério da Saúde. Agência Nacional de Vigilância Sanitária. RDC n.° 67, de 08 de outubro de 2007. Dispõe sobre Boas Práticas de Manipulação de Preparações Magistrais e Oficinas para Uso Humano em farmácias. Brasilia: Ministério da Saúde; 2007. Available from: http://189.28.128.100/dab/docs/resolucao67_08_10.pdf

4. Roque MF. Desenvolvimento de formulações líquidas orais de sildenafil para administração em pediatria [master’s thesis]. Coimbra, PT: UC; 2008.

5. WHO Collaborating Centre for Drug Statistics Methodology Norwegian – Institute of Public Health. ATC/DDD Index 2015. Available from: http://www.whocc.no/atc_ddd_index/ [cited 06.04.15].

6. Melo DO, Ribeiro E, Storpirits S. A importância e a história dos estudos de utilização de medicamentos. Rev Bras Cien Farm. 2006;42:475–85.

7. Oguz SS, Kamniz HG, Dilmen U. Off-label and unlicensed drug use in neonatal intensive care units in Turkey: the old-inn study. Int J Clin Pharm. 2012;34:136–41.

8. Khoury M, Hallak HO, Alayasa KS, AlShahed Q, Hawwaa AF, McElnap JC. Extent and nature of unlicensed and off-label medicine use in hospitalised children in Palestine. Int J Clin Pharm. 2011;33:650–5.

9. Costa PO, Lima JE, Coelho HL. Prescrição e preparo de medicamentos sem formulação adequada para crianças: um estudo de base hospitalar. Braz J Pharm Sci. 2009;45:57–66.

10. Gavrilov V, Berkvitch M, Ling G, Brenner-Zadda G, Lifshitz M, Gorodischer R. Unapproved prescriptions in two pediatric intensive care units in Israel. Curr Ther Res Clin Exp. 2003;64:734–42.

11. Dos Santos L, Heineck I. Drug utilization study in pediatric prescriptions of a university hospital in southern Brazil: off-label, unlicensed and high-alert medications. Farm Hosp. 2012;36:180–6.

12. Neubert A, Wong IC, Bonifazi A, Catapano M, Felisi M, Baiardi P, et al. Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. Pharmacol Res. 2008;58:316–22.

13. Magalhães J, Rodrigues AT, Roque F, Figueiras A, Falcão A, Herdeiro MT. Use of off-label and unlicensed drugs in hospitalised paediatric patients: a systematic review. Eur J Clin Pharmacol. 2015;71:1–13.

14. Santos DB, Clavenna A, Bonati M, Coelho HL. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. Eur J Clin Pharmacol. 2008;64:1111–8.

15. Loureiro CV, Néri ED, Dias HI, Mascarenhas MB, Fontes MM. Uso de medicamentos off-label ou não licenciados para pediatria em hospital público brasileiro. Rev Bras Farm Hosp Serv Saude. 2013;14:17–21.

16. Carvalho CG, Ribeiro MR, Bonilha MM, Fernandes M Jr, Procanoy RS, Silveira RC. Use of off-label and unlicensed drugs in the neonatal intensive care unit and its association with severity scores. J Pediatr (Rio J). 2012;88:465–70.

17. Gonçalves AC, Caixeta CM, Reis AM. Análise da utilização de medicamentos antimicrobianos sistêmicos em crianças e adolescentes em dois hospitais de ensino. Rev Cienc Farm Basica Apl. 2009;30:177–82.

18. Ferreira LA, Ibitapina CC, Machado MG, Fagundes ED. A alta prevalência de prescrições de medicamentos off-label e não licenciados em unidade de terapia intensiva pediátrica brasileira. Rev Assoc Med Bras. 2012;58:82–7.

19. Kimland E, Nydert P, Odland V, Böttiger Y, Lindemalm S. Paediatric drug use with focus on off-label prescription at Swedish hospitals—a nationwide study. Acta Paediatr. 2012;101:772–8.

20. Nguyen KA, Claris O, Kassai B. Unlicensed and off-label drug use in a neonatal unit in France. Acta Paediatr. 2011;100:615–7.

21. Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M, et al. Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatr. 2002;91:339–47.

22. Jong GW, Vulto AG, De Hoog M, Schimmel KJ, Tibboel D, Van Den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics. 2001;108:1089–93.

23. Lass J, Káar R, Jögi K, Varendt H, Metsvaht T, Lutsar I. Drug utilisation pattern and off-label use of medicines in Estonian neonatal units. Eur J Clin Pharmacol. 2011;67:1263–71.

24. O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002;110:e52.

25. Bajecic M, Jelisavcic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R, et al. Off-label and unlicensed drugs use in paediatric cardiology. Eur J Clin Pharmacol. 2005;61:775–9.

26. López Martínez R, Cabañas Poy MJ, Oliveras Arenas M, Clemente B. Utilización de medicamentos en una UCIN neonatal: estudio prospectivo. Farm Hosp. 2005;29:26–9.

27. Di Paolo E, Stoetter H, Cotting J, Frey P, Gehri M, Beck-Popovic M, et al. Unlicensed and off-label drug use in a Swiss paediatric university hospital. Swiss Med Wkly. 2006;136:218–22.

28. Bellis JR, Kikham JJ, Nunn AJ, Pirmohamed M. Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. Br J Clin Pharmacol. 2014;77:545–53.

29. U S Food and Drug Administration. Estados Unidos da América: Drugs@FDA. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ [cited 21.02.15].

30. Messeder AM, Osório-de-Castro CG, Camacho LA. Projeto diagnóstico da farmácia hospitalar no Brasil: uma proposta de hierarquização dos serviços. Cad Saude Publica. 2007;23:835–44.